Mackenzie, Isla

Professor, Professor

  • 3214 Citations
  • 25 h-Index

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile


Professor Isla Mackenzie MBChB (Honours), PhD, FRCP Edin, FBPharmacolS is a Professor of Cardiovascular Medicine and Honorary Consultant Physician at the University of Dundee and Ninewells Hospital, Dundee.  Research interests include cardiovascular safety of drugs, clinical trials, hypertension and technology in research.

Clinical interests include general medicine, hypertension and adrenal disorders including phaeochromocytoma. Professor Mackenzie trained in Clinical Pharmacology in Cambridge prior to moving to Dundee in 2008.


Undergraduate teaching

  • Lectures, seminars, bedside teaching in Clinical Pharmacology/Therapeutics and Medicine (2000 - present)
  •  Marking and question writing for University of Dundee medical student examinations (2008 - present)
  • Medical School Interviews, University of Dundee (2011 - present) 
  • 5th year student portfolio reviewer, University of Dundee (2017- present)
  • Clinical Supervisor - MBPhD students (2000 - 2008)
  • Clinical Pharmacology college supervisions, Cambridge (2000 - 2004)
  • Clinical School Admission Interviews, University of Cambridge (2002 - 2008)

  •  BMSc Cardiovascular Medicine and Diabetes (2018

Postgraduate and multidisciplinary teaching

  • MRCP (PACES) teaching, Tayside (2012 -)
  • Educational / Clinical Supervisor, General Medicine trainees (2012 -)
  • Ward-based and clinical simulator teaching, Cambridge graduate course (2006 - 2008)

  • PASTEST Lecturer in Clinical Pharmacology, London (2005 - 2008)

  •  Bank Physician Trainer for GSK, Cambridge (2005 - 2008)

  •  Member of Clinical Pharmacology Training Committee, Cambridge (2000 - 2005)

  • Contributor to Clinical Pharmacology section of Medical Masterclass Website, Royal College of Physicians London / Blackwell Publishing (2003 -)




My research focuses on improving cardiovascular outcomes and drug safety using a combination of large multicentre randomised clinical trials and pharmacoepidemiological approaches to answer important clinical research questions. I am also interested in clinical trial methodology and improving patient and physician engagement in clinical research. I am Chief Investigator of the ALL-HEART study (involving 424 GP sites and 5,938 patients) and Principal Investigator of other studies. I am Deputy Director of the MEMO Research Unit, University of Dundee with a team of >45 staff and >32,000 patients currently participating in our randomised clinical trials.


Membership of learned societies

  •  British and Irish Hypertension Society (Fellow)
  • British Pharmacological Society (Fellow
  • Caledonian Society of Clinical Pharmacology
  •  Digital Health Institute
  •  International Society for Pharmacoepidemiology
  •  Royal College of Physicians Edinburgh (Fellow)
  •  Scottish Heart and Arterial disease Risk Prevention (SHARP) Group
  •  Scottish Society of Physician


Committee appointments and administrative roles


Part of international consortium of stakeholders leading debate on investigative process into serious adverse outcomes in healthcare product research (2017-) 


Sports Resolutions Panel of Arbitrators and Mediators. Specialist Member of National Anti-Doping Panel (2018-2021)

British Pharmacological Society Membership and Awards Committee (2016-)

British Pharmacological Society Clinical Committee (2016-)

Trustee of Scottish Heart and Arterial disease Risk Prevention (SHARP) Group (2015-)

Representative of the Faculty of Pharmaceutical Medicine on College Council, Royal College of Physicians Edinburgh (2014-2020)

Trustee on Faculty of Pharmaceutical Medicine Board (2014-2020)

Chief Medical Officer’s Specialty Adviser in Clinical Pharmacology (2013-2019)

British Hypertension Society Executive Committee (2012 - 2015). Trustee.

Scottish Society of Physicians Committee (2012 - present). Honorary Secretary of Scottish Society of Physicians (2013 – present)

Royal College of Physicians Edinburgh Symposium Committee (2012 - 2018) and Member of the Symposium Programme Development Panel, RCP Edinburgh (2012 - present)

British Hypertension Society Educational Programmes Working Party (2008 - 2015)

British and Irish Hypertension Society Collaborative Research Working Party (2014-present)

British Pharmacological Society Women in Pharmacology Committee (2007 - 2011)


Deputy Director of Medicines Monitoring Unit and Hypertension Research Centre

Member of MD/MSc Thesis Monitoring Committee, University of Dundee (2013 - present)

Member of Exceptional Medicine and Individual Medicine Requests Panel. Ninewells Hospital, Tayside NHS Trust. (2011 - 2015)

Elected Member of College of Medicine, Dentistry and Nursing College Board, University of Dundee (2013-2015)

Member of School of Medicine Equality, Diversity and Inclusion Committee (2016 - present)

Member of Medicines Monitoring Unit Information Security Forum (2016-present)

Reviewer of potential REF outputs, Molecular and Clinical Medicine (2017, 2018)

Member of School of Medicine Research Management Group (2017-present)

Member of North of Scotland Familial Hypercholesterolaemia Steering Group (2017- present)

Deputy PhD Lead for Division of Molecular and Clinical Medicine, School of Medicine (2018 – present)

Regularly sit on interview panels for University of Dundee/NHS appointments


Trial Steering Committees:

Standard care versus Celecoxib Outcome Trial (SCOT)

Febuxostat versus Allopurinol Streamlined Trial (FAST)

Prevention And Treatment of Resistant Hypertension With Algorithm based TherapY (PATHWAY) 1, 2 and 3 – University of Cambridge, Cambridge (BHF)

Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease (ALL-HEART)

Treatment in the Morning vs the Evening study (TIME)

Lowering Events in Non-proliferative retinopathy in Scotland (LENS), University of Oxford, Oxford



  • R Medicine (General)
  • pharmacoepidemiology
  • Drug Safety
  • randomised clinical trials
  • clinical trial methodology
  • cardiovascular outcomes

Fingerprint Dive into the research topics where Isla Mackenzie is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 14 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.


Research Output

Chronotherapy in hypertension: the devil is in the details

Guthrie, G., TIME study Steering Committee, Poulter, N., Macdonald, T., Ford, I., Mackenzie, I., Findlay, E., Williams, B., Brown, M., Lang, C. & Webb, D., 21 Apr 2020, In : European Heart Journal. 41, 16, p. 1606-1607 2 p.

Research output: Contribution to journalComment/debate

  • Open Access
  • 11 Downloads (Pure)

    Impact of EMA regulatory label changes on systemic diclofenac initiation, discontinuation, and switching to other pain medicines in Scotland, England, Denmark, and The Netherlands

    Morales, D. R., Morant, S. V., MacDonald, T. M., Mackenzie, I. S., Doney, A. S. F., Mitchell, L., Bennie, M., Robertson, C., Hallas, J., Pottegard, A., Ernst, M. T., Wei, L., Nicholson, L., Morris, C., Herings, R. M. C., Overbeek, J. A., Smits, E. & Flynn, R. W. V., Mar 2020, In : Pharmacoepidemiology and Drug Safety. 29, 3, p. 296-305 10 p.

    Research output: Contribution to journalArticle

    Open Access
  • 35 Downloads (Pure)
    Open Access
  • 107 Downloads (Pure)
    2 Citations (Scopus)
    124 Downloads (Pure)


    • 1 Editorial activity
    • 1 Membership of committee

    British Hypertension Society (External organisation)

    Isla S. Mackenzie (Member)


    Activity: Membership typesMembership of committee

    British Journal of Clinical Pharmacology (Journal)

    Isla S. Mackenzie (Editor)

    1 Jan 20121 Jan 2015

    Activity: Publication peer-review and editorial work typesEditorial activity

    Press / Media